<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989348</url>
  </required_header>
  <id_info>
    <org_study_id>shanghaiFMIH-20210729</org_study_id>
    <nct_id>NCT04989348</nct_id>
  </id_info>
  <brief_title>Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol</brief_title>
  <official_title>A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the Progestin-primed Ovarian Stimulation Protocol and the Gonadotrophin Releasing Hormone Antagonist Protocol in Patients With Undergoing Preimplantation Genetic Testing for Aneuploidy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai First Maternity and Infant Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai First Maternity and Infant Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In-vitro fertilization (IVF) involves multiple follicular development, oocyte retrieval and&#xD;
      embryo transfer after fertilization. Despite recent advances in ovarian stimulation, the&#xD;
      method of assisted fertilization and improved culture conditions, the implantation potential&#xD;
      of embryos remains around 30-35% for a long time.&#xD;
&#xD;
      Gonadotrophin releasing hormone (GnRH) agonists have been used in IVF to prevent the LH surge&#xD;
      and the premature ovulation and are given in the luteal phase of the preceding cycle or in&#xD;
      the follicular phase of the treatment cycle i.e. the long GnRH agonist. GnRH antagonists are&#xD;
      now commonly used during IVF. In addition to the advantage of its simplicity, the use of&#xD;
      antagonist is associated with a substantial reduction in ovarian hyperstimulation syndrome&#xD;
      without reducing the chance of achieving live birth when compared with the long agonist&#xD;
      protocols. [1]&#xD;
&#xD;
      Progestin can inhibit the pituitary LH surge during ovarian stimulation and various studies&#xD;
      show progestin-primed ovarian stimulation (PPOS) is effective in blocking the LH surge in IVF&#xD;
      [2-5]. More and more centers in China are using PPOS because this regimen appears simpler and&#xD;
      cheaper. Because of its negative effect on the endometrium, fresh transfer of embryos is not&#xD;
      possible and elective freezing of all embryos is required. PPOS protocol is indicated in&#xD;
      women who freeze all embryos because of various reasons such as undergoing preimplantation&#xD;
      genetic testing for aneuploidy or the risk of ovarian hyperstimulation syndrome.&#xD;
&#xD;
      One prospective non-randomized study comparing the PPOS vs short GnRH agonist protocol shows&#xD;
      similar oocytes retrieved between the two protocols, and the incidence of premature LH surge,&#xD;
      clinical pregnancy rate and live birth rates shows no significant difference. [2] A recent&#xD;
      randomized trial comparing medroxyprogesterone and GnRH antagonist in an oocyte donation&#xD;
      program showed a similar number of mature oocytes but reported lower ongoing pregnancy rate&#xD;
      and live birth rate of recipients of oocyte donors who had received medroxyprogesterone in&#xD;
      IVF [6]. However, the oocyte recipients in that trial were not randomized. Therefore, it is&#xD;
      not possible to conclude the effect of progestin used in IVF on the pregnancy outcomes. It is&#xD;
      possible that the PPOS protocol may have an adverse effect on the euploid rate of embryos,&#xD;
      leading to a lower live birth rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inability to assess embryo quality and select those with the highest potential for&#xD;
      implantation on the basis of morphology has led to the concept of preimplantation genetic&#xD;
      testing for aneuploidy (PGT-A). PGT-A involves biopsy of a few cells from an embryo and&#xD;
      assessment of the chromosome copy numbers. While PGT-A cannot create a healthy embryo or&#xD;
      improve the health of an embryo, it provides a method of selecting embryos with a normal&#xD;
      number of chromosomes for transfer. This in turn has the potential to increase the chance of&#xD;
      having a healthy live birth and reduce the risk of miscarriage or an abnormal fetus caused by&#xD;
      an abnormal number of chromosomes. Aneuploidy screening of all chromosomes is necessary to&#xD;
      determine whether an embryo is chromosomally normal.&#xD;
&#xD;
      As the turnaround time of PGT-A with next generation sequencing is about a week, it is not&#xD;
      possible to transfer blastocyst in the stimulated cycle. All blastocysts will be frozen post&#xD;
      biopsy and the blastocysts with normal genetic makeup will be thawed and replaced in a&#xD;
      subsequent menstrual cycle. Cryopreservation of blastocysts and replacing the frozen&#xD;
      blastocysts after thawing in subsequent cycles become a common practice with vitrification as&#xD;
      the cryopreservation method. A systematic review (7) of the clinical utility of PGT-A with&#xD;
      comprehensive chromosome screening found that three small randomised controlled trials&#xD;
      demonstrated benefit in young and good prognosis patients in terms of clinical pregnancy&#xD;
      rates and the use of single embryo transfer.&#xD;
&#xD;
      This randomized trial aims to compare the euploid rate of blastocysts between PPOS and GnRH&#xD;
      antagonist protocols in patients undergoing PGT-A.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>euploid blastocyst formation rate</measure>
    <time_frame>2 months</time_frame>
    <description>Euploid blastocysts per injected MII oocyte</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of mature oocytes</measure>
    <time_frame>1 month</time_frame>
    <description>M2 oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blastocysts suitable for biopsy and freezing</measure>
    <time_frame>1 month</time_frame>
    <description>blastocysts after extented culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy of the first FET</measure>
    <time_frame>an average of 3 months</time_frame>
    <description>presence of intrauterine gestational sac on ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>an average of 3 months</time_frame>
    <description>number of gestational sacs per embryo transferred</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy of the first FET</measure>
    <time_frame>an average of 6 months</time_frame>
    <description>viable pregnancy beyond gestation 10 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>live birth rate of the first FET</measure>
    <time_frame>average of 1 year</time_frame>
    <description>A baby born alive after 22 weeks gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum FSH level</measure>
    <time_frame>1 month</time_frame>
    <description>hormone level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum AMH level</measure>
    <time_frame>1 month</time_frame>
    <description>hormone level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum estradiol level</measure>
    <time_frame>1 month</time_frame>
    <description>hormone level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum progesterone level</measure>
    <time_frame>1 month</time_frame>
    <description>hormone level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of premature LH surge</measure>
    <time_frame>1 month</time_frame>
    <description>LH ≥10 IU/l</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>IVF</condition>
  <arm_group>
    <arm_group_label>Antagonist group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPOS group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.&#xD;
Gonadotrophin (human menopausal gonadotrophin or recombinant FSH) injections will be started. Ovarian response will be monitored by transvaginal scanning with or without serum hormonal level. Human chorionic gonadotrophin (hCG 1,000 IU) and GnRH agonist (decepepty 0.2mg) will be given for triggering of final maturation when at least 3 follicles reach &gt;17mm in diameter. Blood will be checked for serum estradiol and progesterone levels. Transvaginal USS-guided oocyte retrieval will be performed 36 hours after the trigger.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gonadotrophin releasing hormone antagonist protocol</intervention_name>
    <description>Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger or</description>
    <arm_group_label>Antagonist group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Progestin-primed ovarian stimulation protocol</intervention_name>
    <description>Women will receive oral medroxyprogesterone 10 mg daily or Duphaston 10mg bd from Day 3 till the day of ovulation trigger.</description>
    <arm_group_label>PPOS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of women &lt;43 years at the time of ovarian stimulation for IVF&#xD;
&#xD;
          2. PGT-A indicated for advanced maternal age (&gt;40 years), recurrent miscarriage (&gt;=2 or 3&#xD;
             consecutive miscarriage and repeated implantation failure (&gt;=4 embryos replaced or &gt;=2&#xD;
             blastocysts replaced without success)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of a functional ovarian cyst with E2&gt;100 pg/mL&#xD;
&#xD;
          2. use of donor eggs/sperm,&#xD;
&#xD;
          3. Presence of hydrosalpinx or endometrial polyp which is not surgically treated&#xD;
&#xD;
          4. moderate or severe endometriosis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhi Qin Chen, MD</last_name>
    <phone>86-21-54035201</phone>
    <email>ptchen1@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai first Maternity and Infant health hospital, Tong Ji University</name>
      <address>
        <city>Shanghai</city>
        <zip>200051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011 May 11;(5):CD001750. doi: 10.1002/14651858.CD001750.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD001750.</citation>
    <PMID>21563131</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022. Epub 2015 May 5.</citation>
    <PMID>25956370</PMID>
  </results_reference>
  <results_reference>
    <citation>Dong J, Wang Y, Chai WR, Hong QQ, Wang NL, Sun LH, Long H, Wang L, Tian H, Lyu QF, Lu XF, Chen QJ, Kuang YP. The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial. BJOG. 2017 Jun;124(7):1048-1055. doi: 10.1111/1471-0528.14622.</citation>
    <PMID>28276192</PMID>
  </results_reference>
  <results_reference>
    <citation>Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017 Mar 1;23(2):211-220. doi: 10.1093/humupd/dmw047. Review.</citation>
    <PMID>28062551</PMID>
  </results_reference>
  <results_reference>
    <citation>Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Quan X, Lyu Q, Kuang Y, Ai A. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018 Feb 1;33(2):229-237. doi: 10.1093/humrep/dex367.</citation>
    <PMID>29300975</PMID>
  </results_reference>
  <results_reference>
    <citation>Beguería R, García D, Vassena R, Rodríguez A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod. 2019 May 1;34(5):872-880. doi: 10.1093/humrep/dez034.</citation>
    <PMID>30927417</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee E, Illingworth P, Wilton L, Chambers GM. The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. Hum Reprod. 2015 Feb;30(2):473-83. doi: 10.1093/humrep/deu303. Epub 2014 Nov 28. Review.</citation>
    <PMID>25432917</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai First Maternity and Infant Hospital</investigator_affiliation>
    <investigator_full_name>chen zhi qin</investigator_full_name>
    <investigator_title>clinical doctor in chief</investigator_title>
  </responsible_party>
  <keyword>ppos</keyword>
  <keyword>antagonist protocol</keyword>
  <keyword>PGT-A</keyword>
  <keyword>Euploid Rate of Blastocyst</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Progestins</mesh_term>
    <mesh_term>Hormone Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

